adenine has been researched along with Infections, Plasmodium in 11 studies
Excerpt | Relevance | Reference |
---|---|---|
"Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal administration (five times at 15 mg kg of body weight-1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]." | 7.69 | Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. ( Dorrestein, GM; Franssen, FF; Hermsen, RC; Nieuwenhuijs, H; Overdulve, JP; Smeijsters, LJ, 1996) |
"Plasmodium berghei-infected mice died with low levels of parasitemia after repeated intraperitoneal administration (five times at 15 mg kg of body weight-1 every other day) of the in vitro active antimalarial acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine [(S)-HPMPA]." | 3.69 | Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice. ( Dorrestein, GM; Franssen, FF; Hermsen, RC; Nieuwenhuijs, H; Overdulve, JP; Smeijsters, LJ, 1996) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (54.55) | 18.7374 |
1990's | 2 (18.18) | 18.2507 |
2000's | 1 (9.09) | 29.6817 |
2010's | 2 (18.18) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ondounda, M | 1 |
Tanon, A | 1 |
Ehui, E | 1 |
Ouattara, I | 1 |
Kassi, A | 1 |
Aba, YT | 1 |
Aoussi, EF | 1 |
Kakou, AR | 1 |
Eholié, SP | 1 |
Bissagnene, E | 1 |
Kadio, A | 1 |
Porter, KA | 1 |
Cole, SR | 1 |
Eron, JJ | 1 |
Zheng, Y | 1 |
Hughes, MD | 1 |
Lockman, S | 1 |
Poole, C | 1 |
Skinner-Adams, TS | 1 |
Hosseinipour, M | 1 |
Shaffer, D | 1 |
D'Amico, R | 1 |
Sawe, FK | 1 |
Siika, A | 1 |
Stringer, E | 1 |
Currier, JS | 1 |
Chipato, T | 1 |
Salata, R | 1 |
McCarthy, JS | 1 |
Meshnick, SR | 1 |
Kato, N | 1 |
Sakata, T | 1 |
Breton, G | 1 |
Le Roch, KG | 1 |
Nagle, A | 1 |
Andersen, C | 1 |
Bursulaya, B | 1 |
Henson, K | 1 |
Johnson, J | 1 |
Kumar, KA | 1 |
Marr, F | 1 |
Mason, D | 1 |
McNamara, C | 1 |
Plouffe, D | 1 |
Ramachandran, V | 1 |
Spooner, M | 1 |
Tuntland, T | 1 |
Zhou, Y | 1 |
Peters, EC | 1 |
Chatterjee, A | 1 |
Schultz, PG | 1 |
Ward, GE | 1 |
Gray, N | 1 |
Harper, J | 1 |
Winzeler, EA | 1 |
Tubaro, E | 1 |
Lotti, B | 1 |
Cavallo, G | 1 |
Croce, C | 1 |
Borelli, G | 1 |
Smeijsters, LJ | 1 |
Nieuwenhuijs, H | 2 |
Hermsen, RC | 1 |
Dorrestein, GM | 1 |
Franssen, FF | 2 |
Overdulve, JP | 2 |
de Vries, E | 1 |
Stam, JG | 1 |
Chavalitshewinkoon, P | 1 |
de Clercq, E | 1 |
van der Vliet, PC | 1 |
Jacobs, RL | 1 |
Miller, LH | 1 |
Koontz, LC | 1 |
Lukow, I | 1 |
Schmidt, G | 1 |
Walter, RD | 1 |
Königk, E | 1 |
Muto, T | 1 |
Ebisawa, I | 1 |
Mitsui, G | 1 |
Ilan, J | 2 |
Tokuyasu, K | 1 |
Büngener, W | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Optimal Combination Therapy After Nevirapine Exposure[NCT00089505] | Phase 3 | 745 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Worsening to WHO stage III/IV (among subjects who had WHO stage I/II at baseline) and death were the composite secondary endpoint. WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents is an approach for use in resource limited settings in studies of progression to symptomatic HIV disease. There are 4 stages of disease staging, 1 being the least severe and 4 being the most severe disease stage based on the HIV related symptoms and diagnoses. Please refer to the following web page for detailed staging criteria: http://www.who.int/docstore/hiv/scaling/anex1.html (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 6 |
NVP/LPV_r | 4 |
NoNVP/NVP | 19 |
NoNVP/LPV_r | 26 |
The outcome is defined as treatment-related toxicity (as evaluated by sites), regardless of grade, that led to discontinuation of randomized regimen. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 15 |
NVP/LPV_r | 0 |
NoNVP/NVP | 35 |
NoNVP/LPV_r | 0 |
Virologic failure (VF) is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r.
Intervention | participants (Number) |
---|---|
NVP/NVP | 32 |
NVP/LPV_r | 10 |
NoNVP/NVP | 42 |
NoNVP/LPV_r | 50 |
Any grade of rash or grade 2+ liver lab abnormality events that were claimed to be NVP associated (definitely, probably, or possibly) by site investigators were evaluated. Grade 2+ liver lab abnormality is defined as aspartate aminotransferase (AST)>=2.6 x ULN or alanine aminotransferase (ALT)>=2.6 x ULN. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP arm. Throughout study for NoNVP/NVP arm.
Intervention | participants (Number) |
---|---|
NVP/NVP | 20 |
NoNVP/NVP | 51 |
Change was calculated as the CD4 count at Week 48 (or at Week 96) minus the baseline CD4 count (last CD4 before/on treatment start date). For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r. Throughout study for NoNVP/NVP and NoNVP/LPV_r. Week 48 and 96.
Intervention | cells/mm^3 (Median) | |
---|---|---|
Week 48 CD4 count change from randomization | Week 96 CD4 count change from randomization | |
NoNVP/LPV_r | 172 | 256 |
NoNVP/NVP | 172 | 223 |
NVP/LPV_r | 201 | 278 |
NVP/NVP | 191 | 291 |
Results report cumulative percent of participants reaching virologic failure (VF) or death by week 48 and week 96 calculated using the Kaplan-Meier method. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | Percent of participants (Number) | |
---|---|---|
week 48 percent of virologic failure or death | week 96 percent of virologic failure or death | |
NoNVP/LPV_r | 14 | 20 |
NoNVP/NVP | 14 | 17 |
NVP/LPV_r | 4 | 12 |
NVP/NVP | 23 | 31 |
Self-reported adherence at week 48 and 96 while participants remained on randomized regimen. Adherence interviews for each antiretroviral drug drug the participant is taking was performed by site personnel every 24 weeks. For NVP/NVP and NVP/LPV_r arms, data through DSMB review cutoff (October 6, 2008) were used to report the outcome. For NoNVP/NVP and NoNVP/LPV_r arms, since the follow-up continued as planned, data through overall study were used. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) for NVP/NVP and NVP/LPV_r arms. Throughout study for NoNVP/NVP and NoNVP/LPV_r arms.
Intervention | percent of participants (Number) | |
---|---|---|
week 48 percent of full adherence in past month | week 96 percent of full adherence in past month | |
NoNVP/LPV_r | 86 | 87 |
NoNVP/NVP | 90 | 93 |
NVP/LPV_r | 88 | 95 |
NVP/NVP | 89 | 94 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Through database cutoff for DSMB review (by October 6, 2008) with median follow-up 72 weeks and range from 0 to 144 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NVP/LPV_r | 60 | 84 | NA |
NVP/NVP | 12 | 12 | 60 |
5th and 10th Percentiles in weeks from randomization to virologic failure (VF) or death. VF is defined as a plasma HIV-1 RNA level that is 1 log10 below baseline 12 weeks after treatment is initiated or as a plasma HIV-1 RNA level that is >=400 copies/mL at or after 24 weeks of treatment, regardless of whether randomized treatment was being taken at the time of VF. (NCT00089505)
Timeframe: Throughout study with median follow-up 72 weeks and range from 0 to 180 weeks.
Intervention | weeks (Number) | ||
---|---|---|---|
5th percentile | 10th percentile | 25th percentile | |
NoNVP/LPV_r | 12 | 36 | 132 |
NoNVP/NVP | 24 | 36 | NA |
1 trial available for adenine and Infections, Plasmodium
Article | Year |
---|---|
HIV-1 protease inhibitors and clinical malaria: a secondary analysis of the AIDS Clinical Trials Group A5208 study.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease | 2012 |
10 other studies available for adenine and Infections, Plasmodium
Article | Year |
---|---|
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d | 2011 |
Gene expression signatures and small-molecule compounds link a protein kinase to Plasmodium falciparum motility.
Topics: Adenine; Animals; Antimalarials; Cell Line; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; C | 2008 |
Liver xanthine oxidase increase in mice in three patholgoical models. A possible defence mechanism.
Topics: Adenine; Allopurinol; Animals; Carcinoma, Ehrlich Tumor; Liver; Malaria; Mice; Plasmodium berghei; S | 1980 |
Antimalarial and toxic effects of the acyclic nucleoside phosphonate (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine in Plasmodium berghei-infected mice.
Topics: Adenine; Animals; Antimalarials; Delayed-Action Preparations; Malaria; Mice; Mice, Inbred BALB C; Or | 1996 |
Inhibition of the growth of Plasmodium falciparum and Plasmodium berghei by the DNA polymerase inhibitor HPMPA.
Topics: Adenine; Animals; Antiprotozoal Agents; Binding, Competitive; Cell Line; Deoxyadenine Nucleotides; E | 1991 |
Labeling of sporozoites of Plasmodium berghei with tritiated purines.
Topics: Adenine; Adenosine; Animals; Anopheles; Blood; Deoxyadenosines; Deoxyribonucleosides; Guanosine; Iso | 1974 |
[Adenosine monophosphate salvage synthesis in Plasmodium chabaudi].
Topics: Adenine; Adenosine Monophosphate; Aminohydrolases; Animals; Carbon Radioisotopes; Clinical Enzyme Te | 1973 |
Malaria in Laos. II. Peripheral leucocyte counts during long-term administration of combined folic inhibitors (pyrimethamine with sulformethoxine or sulfamonomethoxine).
Topics: Adenine; Administration, Oral; Aniline Compounds; Asian People; Drug Combinations; Folic Acid Antago | 1971 |
Phosphorylation of D-Arabinosyl adenine by Plasmodium berghei and its partial protection of mice against malaria.
Topics: Adenine; Adenine Nucleotides; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Arabinose; Chr | 1970 |
[Incorporation of exogenous adenosine and hypoxanthine in the nucleic acids of malaria parasites (Plasmodium berghei and Plasmodium vinckei)].
Topics: Adenine; Erythrocytes; Hypoxanthines; Malaria; Nucleosides; Plasmodium; Tritium | 1968 |